stem cell transplantation in patients with acute myeloid leukemia (AML) Azacitidine augments expansion of regulatory T cells after allogeneic
暂无分享,去创建一个
P. Vyas | C. Craddock | P. Moss | Nadira Y. Jilani | O. Goodyear | C. Crawley | R. Malladi | J. Snowden | M. Dennis | M. Raghavan | J. Loke | M. Griffiths | J. Yin | Gordon B Ryan | Jane Nunnick | M. Cook | Rahela Khanum
[1] A. Kiani,et al. Minimal residual disease-directed preemptive treatment with azacitidine in patients with NPM1-mutant acute myeloid leukemia and molecular relapse , 2011, Haematologica.
[2] B. Falini,et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. , 2011, Blood.
[3] Krishna Komanduri,et al. Maintenance therapy with low‐dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome , 2010, Cancer.
[4] C. Craddock,et al. CD8+ T-cell immunity against cancer-testis antigens develops following allogeneic stem cell transplantation and reveals a potential mechanism for the graft-versus-leukemia effect , 2010, Haematologica.
[5] W. Shannon,et al. In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia. , 2010, Blood.
[6] J. Karbach,et al. The DNA demethylating agent 5-aza-2'-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells. , 2010, Leukemia research.
[7] P. Vyas,et al. Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia. , 2010, Blood.
[8] P. Vyas,et al. Factors predicting long-term survival after T-cell depleted reduced intensity allogeneic stem cell transplantation for acute myeloid leukemia , 2010, Haematologica.
[9] N. Kröger,et al. 5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis , 2010, Bone Marrow Transplantation.
[10] H. Dombret,et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] F. J. Gonzalez,et al. Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting. , 2010, Blood.
[12] H. Kantarjian,et al. Low‐dose azacitidine after allogeneic stem cell transplantation for acute leukemia , 2009, Cancer.
[13] K. Rezvani,et al. Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia. , 2009, Blood.
[14] Mario Roederer,et al. High avidity myeloid leukemia-associated antigen-specific CD8+ T cells preferentially reside in the bone marrow. , 2009, Blood.
[15] D. Levy,et al. Epigenetic Regulation of Foxp3 Expression in Regulatory T Cells by DNA Methylation1 , 2009, The Journal of Immunology.
[16] C. Huber,et al. Rapid identification and sorting of viable virus-reactive CD4(+) and CD8(+) T cells based on antigen-triggered CD137 expression. , 2008, Journal of immunological methods.
[17] Christoph Schmid,et al. Matched unrelated or matched sibling donors result in comparable survival after allogeneic stem-cell transplantation in elderly patients with acute myeloid leukemia: a report from the cooperative German Transplant Study Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] K. Kretschmer,et al. DNA methylation controls Foxp3 gene expression , 2008, European journal of immunology.
[19] C. Craddock,et al. Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia. , 2007, Blood.
[20] M. Labopin,et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] P. Greenberg,et al. Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities. , 2007, Blood.
[22] C. Bokemeyer,et al. Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation. , 2007, Blood.
[23] E. Borden,et al. Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] T. Gingeras,et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells , 2006, The Journal of experimental medicine.
[25] W. Selby,et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells , 2006, The Journal of experimental medicine.
[26] M. Maris,et al. Treatment for Acute Myelogenous Leukemia by Low-Dose, Total-Body, Irradiation-Based Conditioning and Hematopoietic Cell Transplantation From Related and Unrelated Donors , 2006 .
[27] C. Fathman,et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation , 2003, Nature Medicine.
[28] A. Nagler,et al. Rituximab reduces relapse risk after allogeneic and autologous stem cell transplantation in patients with high‐risk aggressive non‐Hodgkin's lymphoma , 2003, British journal of haematology.
[29] A. Rudensky,et al. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells , 2003, Nature Immunology.
[30] C. Craddock,et al. Origin and subset distribution of peripheral blood dendritic cells in patients with chronic graft-versus-host disease1 , 2003, Transplantation.
[31] M. Herlyn,et al. Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2'-deoxycytidine. , 1994, Cancer research.
[32] R. Hills,et al. Independent Prognostic Factors for Aml Outcome Pre-treatment Prognostic Factors , 2022 .